Entera Bio Ltd. (ENTX) Form 8-K — Jul 28, 2026
Entera Bio closed a $275 million private placement, issuing approximately 134.8 million ordinary shares and pre-funded warrants at a price of $2.04 per share. The transaction was priced at market and involved institutional investors including BVF Partners L.P., with Leerink Partners acting as the lead placement agent. The company intends to use the net proceeds to fund the initiation of a Phase 3 registrational study for EB613 in postmenopausal women with osteoporosis, alongside general working capital purposes. As part of the agreement, BVF has secured the right to designate two directors to Entera Bio’s board, subject to ownership retention thresholds.
Key figures
- Gross Proceeds
- $275.0 million
- Offering Price
- $2.04
- Shares Offered
- 134,803,910
- Ordinary shares issued
- 122,961,215
- Pre funded warrants issued
- 11,842,695
- Shares outstanding pre offering
- 49,290,196
Price after filing
Close on the filing date to close N calendar days later (from $3.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.